Core Insights - Oncotelic Therapeutics Inc. has selected IBN to lead its corporate communications efforts, aiming to enhance awareness and engagement with investors and the public [1][5][6] Company Overview - Oncotelic is a clinical-stage biopharmaceutical company focused on developing RNA-based immunotherapy and targeted therapeutics for cancer and underserved diseases, particularly in difficult-to-treat and rare conditions [2][7] - The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic ductal adenocarcinoma and has been evaluated for gliomas and metastatic tumors in combination with IL-2 and checkpoint inhibitors [2] Leadership and Innovation - Dr. Vuong Trieu, the Chairman and CEO, has a strong background in the industry, having filed over 500 patent applications with 75 issued to date, and co-invented Abraxane®, which was sold for $2.9 billion [3][8] - Oncotelic holds a 45% stake in GMP Biotechnology Limited, enabling support for regulatory filings for up to 20 drug candidates, and utilizes its proprietary AI platform, PDAOAI, for regulatory workflows and scientific data analysis [4][8] Strategic Partnerships - IBN will utilize its extensive distribution network, which includes over 5,000 syndication outlets and a large social media following, to promote Oncotelic Therapeutics [5][6] - The partnership aims to enhance Oncotelic's visibility among investors, journalists, and the general public, leveraging IBN's experience with over 500 client partners [6][9]